Key Insights

Highlights

Treatment Research

7 treatments under study, led by Imiquimod

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 1 (1)

Trial Status

Not Yet Recruiting1
Recruiting1
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05055050Phase 1Active Not Recruiting

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

NCT07642570Not ApplicableNot Yet RecruitingPrimary

FILLing Protocols for the Right Bladder Volume at the RIGHT Time (FILLRIGHT)

NCT07563764Not ApplicableRecruitingPrimary

Low-Energy Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome

Showing all 3 trials

Research Network

Common Treatments

  • Imiquimod1
  • Quantity A1
  • Quantity B1
  • Quantity D1
  • Sham Shock Wave Therapy1

Active Sponsors

  • M.D. Anderson Cancer Center1
  • KMUHIRB-F(I)-202300511
  • University Hospital, Brest1

Top Investigators

Related Conditions

  • Lower Urinary Track Symptoms1
  • Urgencyfrequency1
  • Bladder Overactive1
  • Bladder Cancer1
  • Metabolic Syndrome1

Activity Timeline